RU2012129882A - Соединение - Google Patents

Соединение Download PDF

Info

Publication number
RU2012129882A
RU2012129882A RU2012129882/04A RU2012129882A RU2012129882A RU 2012129882 A RU2012129882 A RU 2012129882A RU 2012129882/04 A RU2012129882/04 A RU 2012129882/04A RU 2012129882 A RU2012129882 A RU 2012129882A RU 2012129882 A RU2012129882 A RU 2012129882A
Authority
RU
Russia
Prior art keywords
group
substituted
compound
compound according
pharmaceutically acceptable
Prior art date
Application number
RU2012129882/04A
Other languages
English (en)
Russian (ru)
Inventor
Элизер МАСЛАЯ
Эдвард М. РОКЕНШТАЙН
Вольфганг ВРАЗИДЛО
Игорь Флинт ЦИГЕЛЬНИ
Original Assignee
Нейропор Терапиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нейропор Терапиз, Инк. filed Critical Нейропор Терапиз, Инк.
Publication of RU2012129882A publication Critical patent/RU2012129882A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2012129882/04A 2009-12-16 2010-12-16 Соединение RU2012129882A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28708209P 2009-12-16 2009-12-16
US61/287,082 2009-12-16
PCT/US2010/060862 WO2011084642A1 (en) 2009-12-16 2010-12-16 Compound suitable for the treatment of synucleopathies

Publications (1)

Publication Number Publication Date
RU2012129882A true RU2012129882A (ru) 2014-01-27

Family

ID=43629477

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012129882/04A RU2012129882A (ru) 2009-12-16 2010-12-16 Соединение

Country Status (12)

Country Link
US (2) US8846682B2 (OSRAM)
EP (1) EP2513090A1 (OSRAM)
JP (2) JP5922031B2 (OSRAM)
KR (1) KR20120112548A (OSRAM)
CN (1) CN102725284A (OSRAM)
AU (1) AU2010339841B2 (OSRAM)
BR (1) BR112012014807A2 (OSRAM)
CA (1) CA2784744A1 (OSRAM)
MX (1) MX335989B (OSRAM)
NZ (1) NZ600449A (OSRAM)
RU (1) RU2012129882A (OSRAM)
WO (1) WO2011084642A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2867175A1 (en) * 2012-03-28 2013-10-03 Neuropore Therapies, Inc. Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
MX2015000618A (es) * 2012-07-16 2015-04-10 Neuropore Therapies Inc Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas.
US10022357B2 (en) 2013-04-29 2018-07-17 The General Hospital Corporation Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
PE20161393A1 (es) 2014-01-29 2017-01-08 Neuropore Therapies Inc Heteroaril amidas como inhibidores de agregacion de proteina
CN104530013B (zh) * 2014-12-04 2016-06-29 中国农业大学 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
WO2017020010A1 (en) 2015-07-29 2017-02-02 Neuropore Therapies, Inc. Bis-heteroaryl derivatives as modulators of protein aggregation
AU2018212438C1 (en) * 2017-01-26 2021-05-06 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
EP3573981B1 (en) * 2017-01-26 2022-03-16 UCB Biopharma SRL Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
BR112019011932A2 (pt) * 2017-01-26 2019-10-29 Ucb Biopharma Sprl derivados de bis-heteroarila como moduladores da agregação de proteína
WO2018206757A1 (en) 2017-05-11 2018-11-15 Remynd N.V. Inhibitors of pde6delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
DK3621963T3 (da) 2017-05-11 2024-04-15 Remynd N V Forbindelser til behandling af epilepsi, neurodegenerative lidelser og andre CNS-lidelser
EP4458824A1 (en) * 2021-12-27 2024-11-06 Shanghai Jingxin Biomedical Co., Ltd. Fused bicyclic heteroaryl amide compound as protein aggregation inhibitor
TW202415651A (zh) 2022-07-29 2024-04-16 日商住友製藥股份有限公司 含氮飽和雜環衍生物
TW202412787A (zh) 2022-07-29 2024-04-01 日商住友製藥股份有限公司 2(1h)-吡啶亞胺衍生物
WO2024102758A2 (en) * 2022-11-08 2024-05-16 The General Hospital Corporation N-(n-aminoalkyl)phenanthridiunium series of chloride-sensitive fluorophores and methods of use thereof
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726263A3 (en) 1995-02-08 1996-10-09 American Cyanamid Co Herbicides (1,3,4) oxadiazoles and thiadiazoles
US5591695A (en) 1995-02-08 1997-01-07 American Cyanamid Co. Herbicidal [1,3,4]oxadiazoles and thiadiazoles
WO1998027108A2 (en) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
US6096688A (en) 1996-12-27 2000-08-01 American Cyanamid Company Oxazole carboxamide herbicides
US20080293716A1 (en) 2004-01-30 2008-11-27 Smithkline Beecham Corporation Chemical Compounds
CA2580767A1 (en) * 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
KR101394245B1 (ko) * 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
US8541406B2 (en) * 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
EA200870385A1 (ru) * 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. Ингибирование токсичности альфа-синуклеина
WO2009129532A1 (en) * 2008-04-18 2009-10-22 University Of Connecticut Compounds for lysosomal modulation and methods of use
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
AU2010339841B2 (en) 2014-09-25
NZ600449A (en) 2014-10-31
WO2011084642A1 (en) 2011-07-14
EP2513090A1 (en) 2012-10-24
MX2012006740A (es) 2012-09-07
JP5922031B2 (ja) 2016-05-24
BR112012014807A2 (pt) 2017-06-27
US8846682B2 (en) 2014-09-30
JP2016074679A (ja) 2016-05-12
AU2010339841A1 (en) 2012-07-05
KR20120112548A (ko) 2012-10-11
CA2784744A1 (en) 2011-07-14
CN102725284A (zh) 2012-10-10
US20140364610A1 (en) 2014-12-11
US20130035342A1 (en) 2013-02-07
JP2013514980A (ja) 2013-05-02
MX335989B (es) 2016-01-07

Similar Documents

Publication Publication Date Title
RU2012129882A (ru) Соединение
ES2795366T3 (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas
US8809552B2 (en) Azetidine compounds, compositions and methods of use
BRPI0620201A2 (pt) derivados de pirimidina
US9586961B2 (en) Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
RU2007119307A (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[3, 2-d]ПИРИМИДИН-4-ОНА И ИХ ПРИМЕНЕНИЕ В ТЕРИПИИ
ES2973331T3 (es) Compuesto de [1,2,4]triazolo[1,5-a]piridina como inhibidor de JAK y aplicación del mismo
MA30360B1 (fr) Dérivés pyrimidiniques utilisés comme inhibiteurs de la pi3k
RU2007119373A (ru) Фармацевтические соединения
KR20160141859A (ko) 신규 2치환 1,2,4-트리아진 화합물
CN114430740A (zh) Egfr抑制剂、组合物及其制备方法
NZ605528A (en) Ip receptor agonist heterocyclic compounds
NZ572600A (en) 6-Amino-purine derivatives for the treatment of cancer and fibrogenetic disorders
HRP20120077T1 (hr) Benzimidazolonski spojevi s aktivnošću agonista 5-ht4 receptora
NZ599860A (en) Carboxamide compounds and their use as calpain inhibitors
KR20100045440A (ko) 11-베타 하이드록실 스테로이드 데하이드로게나제 1형의 억제제로서의 스피로사이클
WO2003087064A1 (en) Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
JP2011510929A5 (OSRAM)
MX2009010884A (es) 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k).
WO2006040966A1 (ja) 芳香環縮合ピリミジン誘導体
NZ603896A (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
JP2012507525A5 (OSRAM)
JP2014520108A5 (OSRAM)
CZ56298A3 (cs) 2,3-dioxo-1,2,3,4-tetrahydrochinoxalinylové deriváty, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
JP2014530807A (ja) H3受容体阻害剤としてのピペリジン及びピペラジン環を含むカルバメート/尿素誘導体

Legal Events

Date Code Title Description
FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20141224

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20161108